… (T315I) of the BCR-ABL protein was the first mutation detected in … Sequencing of cloning
products revealed the T315I mutation … Mutant BCR-ABL alleles retain biologic activity but show …

… Clinical data indicate that developing BCRABL mutations during imatinib … on mutation type
or location. in vitro, dasatinib and nilotinib inhibit most imatinib-resistant BCR-ABL mutations, …

… BCR-ABL gene amplification, BCR-ABL over-expression, aberrations in other signaling
pathways, and a host of others. Point mutations in the BCR-ABL … Mutations in the kinase domain …

… We describe a screen for such mutations in patients with … We hypothesized that coexpressing
BCR-ABL deletion mutants … coexpression of native and deletion mutant BCR-ABL in Ba/F3 …

… caused by point mutations within the kinase domain of Bcr-Abl. New Abl kinase inhibitors
with higher potency against native and imatinib-resistant mutants of Bcr-Abl could have …

… that expression of BCR–ABL led to a small but significant increase in point mutations in
BCR–ABL-expressing cells in vivo. However, it is still unresolved whether point mutations are a …

… suppressed the Bcr-Abl dependent phenotype and inhibited Bcr-Abl kinase … loop mutant
Bcr-Abl H396P as effectively as wild-type Bcr-Abl. In addition, nucleotide-binding loop mutations …

… Another approach to overcoming the T315I mutation is to target regions of Bcr-Abl outside
of the ATP binding site. ON44580 (Onconova Therapeutics, Newtown, PA) has shown promise …

… the action of imatinib in suppressing proliferation of a murine cell line (Ba/F3) transduced
with mutated BCRABL genes [40] . In general, the degree of imatinib resistance manifested by …

… of CML research are the role of Bcr-Abl–independent mechanisms in … BCR-ABL mutant
allele does not always explain clinical resistance to imatinib. Here we review BCR-ABL mutations …